Bladder cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• MYC 0
• ERK 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

24 of 60+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Artificial Intelligence Enhanced Detection and Monitoring of Bladder Cancer

  Vesica Corporation· San Marcos, United States· US$1,200,764 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort

  Veterans Education/Res/Assn/North/Ne· White River Junction, United States· US$594,869 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Population modeling for bladder cancer prevention and control

  Brown University· Providence, United States· US$1,231,387 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · P50

  SPORE in Bladder Cancer

  Sloan-Kettering Inst Can Research· New York, United States· US$2,491,899 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the effect of high methionine availability on cancer progression

  University of Southern California· Los Angeles, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €2,000,000· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €197,264· until Mar 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Ireland· EU contribution €328,495· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Ireland· EU contribution €13,615,935· until Dec 2029· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Israel· EU contribution €2,498,731· until Nov 2026

10 of 192 running projects, newest first. Listed amounts together: US$123.2m + €36.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

  NCT06571708· Columbia University· Updated 3 Nov 2026

  “Change in standard of care treatment for muscle-invasive bladder cancer”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Astellas Pharma Global Development, Inc.· Updated 24 Mar 2026

  “Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

  NCT06580938· Pfizer· Updated 23 Mar 2026

  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Terminated

  A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

  NCT06285097· Pfizer· Updated 17 Sept 2025

  “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

  NCT06448364· Pfizer· Updated 6 Nov 2024

  “Strategic business decision”Registry text, quoted unchanged. Source

• Terminated

  LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

  NCT04690699· Istari Oncology, Inc.· Updated 24 Oct 2024

  “business decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

  NCT04579224· National Cancer Institute (NCI)· Source

• A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

  NCT05562830· Merck Sharp & Dohme LLC· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

  NCT03711032· Merck Sharp & Dohme LLC· Source

• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Pfizer· Source

• Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

  NCT07625527· Tianjin Medical University Second Hospital· Source

• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Merck Sharp & Dohme LLC· Source

• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Merck Sharp & Dohme LLC· Source

• Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  NCT06439836· National Cancer Institute (NCI)· Source

• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

  NCT04700124· Merck Sharp & Dohme LLC· Source

• A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

  NCT05661955· BeiGene· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 79
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 78
• Genome-Wide Association Study 18

• Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort.

  JCO Precis Oncol, Nov 2026

• Elevated Risk of Bladder Cancer Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease in Elderly Korean Men: A Nationwide Cohort Study.

  J Korean Med Sci, Nov 2026

• Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non-Muscle-Invasive Bladder Cancer.

  JCO Precis Oncol, Nov 2026

• Overall Survival After Neoadjuvant Versus Adjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Real-world Multicenter Cohort Study.

  Anticancer Res, Nov 2026

• Clinical response outweighs baseline nodal stage in treatment selection and survival of clinically node-positive bladder cancer.

  World J Urol, Oct 2026

• FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.

  Medicina (Kaunas), Oct 2026

• Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.

  ESMO Open, Sept 2026

• Oncological and perioperative outcomes of robot-assisted radical cystectomy: a real-world cohort study emulating a target trial.

  J Robot Surg, Sept 2026

• Soy Consumption and the Risk of Developing Bladder Cancer: A Pooled Analysis of Cohort Studies from the International Pooled Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study.

  Nutrients, Sept 2026

• Association between cervical human papillomavirus infection and bladder cancer risk: A community-based cohort study.

  J Infect Public Health, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.